The best way to heal

  • Description
  • Benefits
  • Indications
  • In Practice
  • FAQs
  • Evidence
  Download product information

Discover UrgoStart

UrgoStart is the only wound dressing with demonstrated superiority in wound healing speed:UrgoStart heals wounds twice as fast as a neutral absorbent dressing (1)

Soft adherent foam dressing with TLC-NOSF

Accelerating healing while generating savings

nudgex2

  • Heals twice as fast as a neutral dressing(1)  and avoids wounds becoming longstanding
  • Is cost-effective
  • Improves patients’ quality of life (1)

 

COMPOSITION

UrgoStart is a soft-adherent foam dressing with TLC-NOSF, comprised of:

  • A soft-adherent TLC-NOSF layer combined with an absorbent polyurethane foam pad,
  • A vapour permeable outer film.

 

urgostart-composition-3 

Mode of Action

TLC (Technology Lipido-Colloid) combined with NOSF (Nano-Oligo Saccharide Factor) is a patented innovative technology which in contact with wound exudate forms a gel and creates a moist environment enabling the key cells involved in the repair process (fibroblasts, keratinocyrtes, macrophages) to exert their action.

TLC-NOSF interacts with the wound micro-environment of the wound by preventing the detrimental effect of Matrix Metallo Proteases (MMPs) which in excess in chronic wounds creates a continuous degradation of the extra-cellular matrix. TLC-NOSF restores balance in the wound bed so granulation of chronic wounds can occur. UrgoStart thereby promotes faster wound healing.

TLC NOSF Technology

* Studies on pathophysiological mechanisms in healing have demonstrated the essential role of proteases (MMPs) in the persistence of inflammatory responses and the slowing of wound healing (2, 3, 4, 5). Proteases are enzymes that participate in the physiological wound cleansing process; they help set the stage for healing. However, when subcutaneous tissue is ischaemic, for example in arterial disease or diabetes, the presence of proteases becomes excessive, causing persistent inflammation and dermal destruction (2). This excess of proteases has been observed in leg, pressure and diabetic foot ulcers, the three major types of chronic wounds (2,3,4,5).
 
(1) Meaume S, et al.A randomized, controlled, double-blind prospective trial with a Lipido-Colloid Technology-Nano-OligoSaccharide Factor wound dressing in the local management of venous leg ulcers. Wound Repair and Regeneration 2012 (July/August);Vol 20:500-511.
(2) Kirsner et al. Wounds, 2002,vol 13, N°3, May/june,
(3) R Lobmann. Diabetologia 2002 ; 45:1011–1016
(4) Y Liu. Diabetes Care 2009; 32:117–9
(5) A Moore. Wound Rep Regen 2009;17:832-39

This website is an international website. Some products or sizes can therefore be unavailable in some countries. For more information, please contact us.

Benefits for the wound

  • Heals twice as fast (1)
  • Avoids wounds becoming longstanding with associated risks of complications
  • Neutralisation of excess proteases
  • Vertical absorption and retention of exudate
  • Moist wound healing
  • Fibroblast proliferation
  • No adherence to the wound : no damage to newly formed tissue
  • Protection and improvement of peri-wound skin
  • Can be left in place for up to 7 days – fewer dressing changes reducing healing disturbance
  • High conformability to the wound bed

benefits-for-professionnalBenefits for health professionals

  • Heals twice as fast as a neutral foam dressing(1)
  • Avoids wounds becoming longstanding with associated risks of complications
  • Clinically proven in a double blind Randomised Controlled Trial
  • Cost effective treatment
  • Improves patient quality of life: less anxiety, less depression, less pain(1)
  • Exudate management
  • Easy to apply
    • Stays in place when applied
    •  Easy to reposition without losing its gentle adherence
  • Easy to remove with pain-free dressing changes
  • Can be used under compression
  • Can be left in place for up to 7 days – fewer dressing changes

benefits-for-patientBenefits for patients

  • Faster recovery (1)
  • Avoids wounds becoming longstanding with associated risks of complications
  • Improved patient quality of life: less anxiety, less depression, less pain (1)
  • No adherence to the wound: pain-free dressing changes
  • Well tolerated
  • Very conformable and comfortable
  • Can be left in place for up to 7 days – fewer dressing changes
(1) Meaume S, et al.A randomized, controlled, double-blind prospective trial with a Lipido-Colloid Technology-Nano-OligoSaccharide Factor wound dressing in the local management of venous leg ulcers. Wound Repair and Regeneration 2012 (July/August);Vol 20:500-511.

UrgoStart is indicated for exuding chronic wounds (leg ulcers, pressure ulcers, diabetic foot ulcers, longstanding acute wounds)

Contraindications

In order not to delay any optimal treatment, UrgoStart is contraindicated in wounds such as cancerous wounds or fistula wounds which may reveal a deep abscess.

Do not used if there is a known sensitivity to UrgoStart.

mode_emploi_urgostartInstructions for use

  • Clean the wound as per local protocol and rinse with normal saline.
  • If an antiseptic is first used, rinse the wound thoroughly with saline solution before applying UrgoStart.
  • UrgoStart can be cut using sterile scissors to fit the dressing size to the wound if necessary.
  • Using the tabs, remove the protective film.
  • Apply the soft-adherent side of UrgoStart to the wound.
  • If required, cover UrgoStart with a secondary dressing suitable for the location and level of wound exudate.
  • Secure the dressing in place with a suitable bandage or an adhesive tape. Apply a compression bandage when prescribed.
  • UrgoStart should be changed every 2 to 4 days, and left in place for up to 7 days depending on the level of exudate and the clinical condition of the wound.
  • The recommended treatment duration for UrgoStart is a minimum of 8 weeks until wound healing.

Application of the heel version

  • The dressing is an arrow shape. Remove the protective wings.
  • Place the foot pointing in the direction of the arrow with the heel in the centre of the soft-adherent TLC (narrow part).
  • Fold the back of the dressing up and around the back of the heel. Mold the side edges up and around the foot.
  • Secure the dressing in place with a suitable bandage.

Precautions for use

  • As the soft-adherent layer of UrgoStart adheres to surgical gloves (latex), it is recommended to use the protective wings to aid application.
  • If signs of critical colonisation are present, suitable treatment is recommended before using UrgoStart.
  • In case of an atypical ulcer presenting induration or overgranulation, UrgoStart should only be used after checking the absence of wound-related malignancy in order not to delay the diagnosis.
  • The action of the product on the healing process may possibly cause stinging or painful sensations at the start of treatment with UrgoStart. This rarely warrants suspension of treatment
  • In the absence of clinical data as a first line treatment in acute wounds, and in the treatment of Epidermolysis bullosa (even for longstanding lesions), it is not recommended to use UrgoStart.
  • Discard any unused parts of the dressing.
  • Check that the sterility protector is intact before use.
  • Single-use, individual and sterile dressing: re-using a single-use product may lead to risks of infection.
  • Do not re-sterilise the dressing.

Sizes available

  • 6×6 cmUrgoStart 10x10
  • 10×10 cm; 10×12 cm; 13×12 cm
  • 15×15 cm; 15×20 cm
  • Heel 12 x 19 cm

 


This website is an international website. Some products or sizes can therefore be unavailable in some countries. For more information, please contact us.

Product

What is UrgoStart?

UrgoStart is a soft-adherent foam dressing with, comprising a TLC-NOSF layer with an absorbent polyurethane foam pad and a vapour permeable outer film.

How does UrgoStart work?

TLC (Technology Lipido-Colloid) combined with NOSF (Nano-Oligo Saccharide Factor) is a patented innovative technology which in contact with wound exudate forms a gel and creates a moist environment enabling the key cells involved in the repair process (fibroblasts, keratinocyrtes, macrophages) to exert their action.

TLC-NOSF interacts with the wound micro-environment of the wound by preventing the detrimental effect of Matrix Metallo Proteases (MMPs) which in excess in chronic wounds creates a continuous degradation of the extra-cellular matrix. TLC-NOSF restores balance in the wound bed so granulation of chronic wounds can occur. UrgoStart thereby promotes faster wound healing.

What is the role of the soft-adherence?

The soft-adherence makes UrgoStart very conformable and flexible, ensuring close contact with the wound bed to promote healing.  Due to the soft-adherence, UrgoStart stays in place when applied, aiding dressing changes.

Why do you say that UrgoStart is cost-effective?

Due to improved healing rates, UrgoStart reduces overall treatment time, and therefore the number of nurse visits and the associated costs.

Indications

When should I use UrgoStart?

UrgoStart is indicated for exuding chronic wounds (leg ulcers, pressure ulcers, diabetic foot ulcers, longstanding acute wounds…).

Can I use UrgoStart during the epithelialisation stage?

Yes.

Can I use UrgoStart in desloughing stage?

For desloughing, UrgoClean is recommended as the best option.

Can I use UrgoStart on infected wounds?

In the case of an infected wound, an antibacterial dressing should be used before using UrgoStart.

What are the contraindications of UrgoStart?

In order not to delay any optimal treatment, UrgoStart is contraindicated in wounds such as cancerous wounds or fistula wounds which may reveal a deep abscess.

Do not used if there is a known sensitivity to UrgoStart.

Use

UrgoStart can adhere to gloves. How should I avoid this?

It is recommended to use the protective wings to facilitate application.

Which side of UrgoStart should I apply to the wound?

The soft-adherent side of UrgoStart should be applied to the wound.

cutting-dressing-guide

Cutting Guide

Can I cut UrgoStart?

Yes.

How can I secure UrgoStart?

If required, cover UrgoStart with a secondary dressing suitable for the location and level of wound exudate.  Secure the dressing in place with a suitable bandage, adhesive tape, or apply a compression bandage when prescribed.

Can I use UrgoStart under compression?

Yes. UrgoStart has an excellent ability to retain exudate even under compression.

When should I change UrgoStart?

UrgoStart should be changed every 2 to 4 days (up to 7 days) depending on the level of exudate and the clinical condition of the wound.

The wound seems larger after treatment with UrgoStart. Is this to be expected?

It has been demonstrated that the wound may initially appear larger after treatment with UrgoStart, before reducing in size. Continuing treatment with UrgoStart is essential to promote faster healing.

My patient complains with pain/stinging, is this to be expected?

In some cases, this has been noted during the initial stages. However, if the patient is able to tolerate it, continued treatment with UrgoStart is essential to promote faster healing.

Evidence

What evidence do you have?

The efficacy of TLC-NOSF has been clinically proven in:

  • Challenge Study, a Double blind Randomised Controlled Trial demonstrating that it heals twice as fast as a neutral foam dressing (with the foam version – UrgoStart)
  • A randomized Controlled Trial (with the contact layer version – UrgoStart Contact)
  • Observational studies
  • Several clinical studies on leg ulcers, pressure ulcers and diabetic foot ulcers

What is a double blind Randomised Controlled Trial?

A double blind Randomised Controlled Trial is the most superior level of evidence required by Heath Authorities.

“Randomised” means that patients are chosen at random to be included in either of the two groups.

“Controlled” means that the treatment is tested against another treatment that has proven its efficacy.

“Double blind” means that both tested treatments are similar in aspect, and neither the clinician/nursing staff, nor the patient knows which treatment is being used, avoiding any risk of bias.

UrgoStart range has been evaluated in numerous European clinical studies involving patients with different types of wounds, in particular leg ulcers, pressure ulcers and diabetic foot ulcers.

Its clinical efficacy has been demonstrated for venous or mixed predominantly venous ulcers in two comparative controlled clinical studies, one vs Promogran and another, the Challenge study, vs a neutral dressing.

 

Urgo_Review_resize_A4_web poster-01-rethore-v3 poster-02-leger-v3
Supporting evidence-based practice: a clinical review of TLC technology Effect of a new metalloproteinase inhibitor (NOSF) in the local management of pressure ulcers – Results of a clinical study Management of venous leg ulcers with a lipidocolloid matrix impregnated with NOSF (Nano-Oligosaccharide Factor) – Results of a clinical study
Download Download Download

 

A randomized, controlled, double-blind prospective trial with a Lipido-Colloid Technology-Nano-OligoSaccharide Factor wound dressing in the local management of venous leg ulcers

Meaume S. et al, Wound Rep Reg (2012) 20 500–511 © 2012 by the Wound Healing Society

Venous leg ulcers (VLUs) are the most prevalent chronic wounds in western countries with a heavy socioeconomic impact. Compression therapy is the etiologic treatment of VLU but until now no wound dressing has been shown to be more effective than another. The aim of this study was to assess the efficacy of a new dressing in the management of VLU. Adult patients presenting a noninfected VLU and receiving effective compression therapy were enrolled in this randomized, controlled, double-blind trial. The VLUs were assessed every 2 weeks for 8 weeks. The primary study outcome was the relative Wound Area Reduction (WAR, in %), and the secondary objectives were absolute WAR, healing rate, and percentage of wounds with > 40% surface area reduction. One hundred eighty-seven patients were randomly allocated to treatment groups. Median WAR was 58.3% in the Lipido-Colloid Technology-Nano-OligoSaccharide Factor (TLC-NOSF) dressing group (test group) and 31.6% in the TLC dressing group (control group) (difference: – 26.7%; 95% confidence interval: – 38.3 to – 15.1%; p = 0.002). All other efficacy outcomes were also significant in favor of the TLC-NOSF dressing group. Clinical outcomes for patients treated with the new dressing are superior to those patients treated with the TLC dressing (without NOSF compound), suggesting a strong promotion of the VLU healing process.

Last update : November 23, 2017